- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04233346
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
A Phase II Multi-center, Randomized, Open-label Study of Ponatinib in Chinese Patients With Chronic Myeloid Leukemia Who Have Failed Prior TKIs or With T315I Mutation, or Ph+ALL Who Have Failed Prior TKIs or With T315I Mutation
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Beijing, China
- 1st affiliated hospital, Peking University
-
Tianjin, China
- Hematology Hospital, Chinese Academy of Medical Sciences
-
-
Anhui
-
Hefei, Anhui, China
- Anhui Provincial Hospital
-
Hefei, Anhui, China
- The First Affiliated Hospital of Anhui Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Nanfang Hospital of Southern Medical University
-
-
Hubei
-
Wuhan, Hubei, China
- Tongji Hospital affiliated to Tongji Medical College, Huazhong University of Science and Technology
-
-
Hunan
-
Changsha, Hunan, China
- Xiangya Hospital Central South University
-
-
Jiangsu
-
Suzhou, Jiangsu, China
- The First Affiliated Hospital of Soochow University
-
-
Liaoning
-
Shenyang, Liaoning, China
- Shengjing Hospital Of China Medical University
-
-
Shandong
-
Jinan, Shandong, China
- Qilu Hospital of Shandong University
-
-
Shanxi
-
Taiyuan, Shanxi, China
- Second Hospital of Shanxi Medical University
-
-
Shenzhen
-
Shenzhen, Shenzhen, China
- Shenzhen Second People's Hospital
-
-
Sichuan
-
Chengdu, Sichuan, China
- West China Hospital, Sichuan University
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- The First Affiliated Hospital of Medical School of Zhejiang University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
For CP-CML patients:
Patients with CP-CML
Patients must either meet criterion 2 or 3:
- Be previously treated with and resistant or intolerant to either Dasatinib or Nilotinib:
- Develop the T315I mutation after any TKI therapy;
- Must be ≥18 years old.
- Provide written informed consent.
- Eastern Cooperative Oncology Group performance status ≤ 2.
- Minimum life expectancy of 3 months or more.
- Adequate renal function
- Adequate hepatic function
- Normal pancreatic status
- Normal QTc interval on screening electrocardiogram (ECG) evaluation under resting state, defined as QTc of ≤ 450 ms in males or ≤ 470 ms in females.
For AP/BP-CML and ALL patients:
- Patients with AP-CML and BP-CML or Ph+ ALL
- Other inclusions are the same with No.2-No.11 of CP-CML patients
Exclusion Criteria:
For CP-CML patients:
- Received TKI therapy within 7 days prior to receiving the first dose of Ponatinib, or have not recovered (> grade 2 by NCI CTCAE v5.0) from AEs (except alopecia) due to agents previously administered.
Received other therapies (excluding hydroxyurea) as follows:
Received interferon, cytarabine, or immunotherapy within 14 days, or any other cytotoxic chemotherapy, radiotherapy, or investigational therapy within 28 days prior to receiving the first dose of Ponatinib.
- Underwent autologous or allogeneic stem cell transplant < 60 days prior to receiving the first dose of Ponatinib;
- Take medications that are known to be associated with Torsades de Pointes or QT interval prolongation.
- Require concurrent treatment with immunosuppressive agents, other than corticosteroids prescribed for a short course of therapy.
- Have previously been treated with Ponatinib or its analogues (including drug substance).
- Patients with CP-CML are excluded if they are in CCyR.
- Have active central nervous system (CNS) disease, as evidenced by cytology or pathology.
- Have significant, uncontrolled, or active heart/brain/peripheral vascular diseases
- Have a significant bleeding disorder unrelated to CML
- Have a history of pancreatitis or alcohol abuse
- Severely increased hypertriglyceridemia (triglycerides ≥ 5.6 mmol/L).
- Have malabsorption syndrome or other gastrointestinal illness that could affect absorption of orally administered Ponatinib.
- Have been diagnosed with another primary malignancy within the past 3 years (except for non-melanoma skin cancer, cervical cancer in situ, or controlled prostate cancer, which are allowed within 3 years).
- Are pregnant or lactating.
- Underwent major surgery (with the exception of minor surgical procedures, such as catheter placement or BM biopsy) within 14 days prior to first dose of Ponatinib.
- Infectious diseases test showed anti-HIV (+) or anti-HCV (+) or HbsAg (+) or TP (+).
- Suffer from any condition or illness that, in the opinion of the investigator, would compromise patient safety or interfere with the evaluation of the safety of the study drug.
- Have hypertension (diastolic blood pressure ≥ 90 mmHg and/or systolic blood pressure ≥ 140 mm Hg).
- Taken herbal preparations or related over-the-counter preparations containing Chinese herbal ingredients within 2 weeks prior to the first dose of Ponatinib.
- Any subject who is not suitable for the study in the opinion of the investigator.
For AP/BP-CML and ALL patients:
- Received TKI therapy within 7 days prior to receiving the first dose of Ponatinib, or have not recovered (> grade 2 by NCI CTCAE v.5.0) from AEs (except alopecia) due to agents previously administered.
Received other therapies (excluding hydroxyurea) as follows:
For AP-CML patients, received interferon, cytarabine, or immunotherapy within 14 days, or any other cytotoxic chemotherapy, radiotherapy, or investigational therapy within 28 days prior to receiving the first dose of Ponatinib.
For BP-CML patients, received chemotherapy within 7 days prior to the first dose of Ponatinib. Otherwise, 2a applies.
For Ph+ ALL patients, received corticosteroids within 24 hours before the first dose of Ponatinib; otherwise, 2a applies.
- Underwent autologous or allogeneic stem cell transplant < 60 days prior to receiving the first dose of Ponatinib.
- Take medications that are known to be associated with Torsades de Pointes or QT interval prolongation.
- Require concurrent treatment with immunosuppressive agents, other than corticosteroids prescribed for a short course of therapy.
- Have previously been treated with Ponatinib or its analogues (including drug substance).
- Patients with AP-CML, BP-CML, or Ph+ ALL are excluded if they are in MaHR.
- Patients with AP-CML, BP-CML, or Ph+ ALL are excluded if a baseline BM aspirate adequate for cell count and differential report is not available.
- Have active central nervous system (CNS) disease as evidenced by cytology or pathology for AP-CML, BP-CML, or Ph+ ALL.
- Have significant, uncontrolled, or active cardiovascular disease.
- Have a significant bleeding disorder unrelated to CML or Ph+ ALL.
- Other exclusions are the same with No.11-No.21 of CP-CML.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ponatinib
CP-CML:Chronic Phase Chronic Myeloid Leukemia; AP-CML:Accelerated Phase Chronic Myeloid Leukemia; BP-CML:Blast Phase Chronic Myeloid Leukemia; Ph+ ALL:Ph+ Acute Lymphoblastic Leukemia;
|
CP-CML patients will be randomized into 30 mg and 45 mg dose groups at the ratio of 1:1,each group taken orally once daily.
Other patients taken 45mg orally once daily.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MCyR(Major Cytogenetic Response) of CP-CML patients
Time Frame: 12 months
|
To confirm the efficacy of Ponatinib in Chinese patients with CML who have failed Dasatinib or Nilotinib or with T315I mutation, or Ph+ ALL who have failed prior TKIs or with T315I mutation as evidenced by cytogenetic responses
|
12 months
|
MaHR(Major Hematologic Response) of AP-CML, BP-CML and Ph+ ALL patients by 6 months
Time Frame: 6 months
|
To confirm the efficacy of Ponatinib in Chinese patients with CML who have failed Dasatinib or Nilotinib or with T315I mutation, or Ph+ ALL who have failed prior TKIs or with T315I mutation as evidenced by hematology responses
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of response
Time Frame: Up to 5 years
|
Assessment in the total patient population
|
Up to 5 years
|
Progression-free survival (PFS)
Time Frame: Up to 5 years
|
Assessment in the total patient population
|
Up to 5 years
|
Overall survival (OS)
Time Frame: Up to 5 years
|
Assessment in the total patient population
|
Up to 5 years
|
Time to response (TTR)
Time Frame: Up to 5 years
|
Assessment in the total patient population
|
Up to 5 years
|
Adverse events
Time Frame: Up to 5 years
|
Number of participants with adverse events as assessed by CTCAE v5.0
|
Up to 5 years
|
EORTC QLQ-C30 (version 3)
Time Frame: Up to 5 years
|
EORTC QLQ-C30 (version 3) score ranges from 1 to 4 or 1 to 7, A higher score represents a severer impressions or a best applies of patients.
|
Up to 5 years
|
Maximum Plasma Concentration [Cmax]
Time Frame: Up to 3 months
|
Plasma concentration-time data for the population PK study
|
Up to 3 months
|
Collaborators and Investigators
Investigators
- Study Director: Juma Paty, Director, OBRI
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Leukemia, Lymphoid
- Chronic Disease
- Leukemia
- Leukemia, Myeloid
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Ponatinib
Other Study ID Numbers
- 297-403-00003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Lymphoblastic Leukemia
-
National Cancer Institute (NCI)CompletedB-cell Adult Acute Lymphoblastic Leukemia | Acute Undifferentiated Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingAcute Lymphoblastic Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Adult T Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Adult L1 Acute Lymphoblastic Leukemia | Adult L2 Acute Lymphoblastic...United States
-
Autolus LimitedCompletedCD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (AMELIA)Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | Refractory Childhood Acute Lymphoblastic LeukemiaUnited Kingdom
-
Children's Oncology GroupNational Cancer Institute (NCI); ImmunoGen, Inc.WithdrawnRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | Refractory Mixed Phenotype Acute Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent...
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Non-T, Non-B Childhood Acute Lymphoblastic LeukemiaUnited States
-
University College, LondonNot yet recruitingAcute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved Remission
-
University of BirminghamAstraZeneca; Cancer Research UKTerminatedAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia RecurrentUnited Kingdom, Denmark, Netherlands
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Graft Versus Host Disease | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinRecruitingAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved RemissionUnited States
-
Therapeutic Advances in Childhood Leukemia ConsortiumEnzon Pharmaceuticals, Inc.TerminatedLymphoblastic Leukemia, Acute, Childhood | Leukemia, Lymphoblastic, Acute | Lymphoblastic Leukemia, Acute | Leukemia, Lymphoblastic, Acute, T CellUnited States, Australia
Clinical Trials on Ponatinib
-
Associazione Italiana Pazienti Leucemia Mieloide...Not yet recruitingChronic Myeloid Leukemia (CML)Italy
-
Ariad PharmaceuticalsCompletedChronic Myeloid Leukemia (CML) | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)Japan
-
Dana-Farber Cancer InstituteCompleted
-
Memorial Sloan Kettering Cancer CenterCompletedNon Small Cell Lung Cancer | KRAS Gene MutationUnited States
-
Dana-Farber Cancer InstituteTerminatedNon-Small Cell Lung Cancer, Head and Neck CancerUnited States
-
Ariad PharmaceuticalsTerminatedChronic Phase Chronic Myeloid LeukemiaBelgium
-
Sebastian BauerHannover Medical School; University Hospital Tuebingen; Universitätsmedizin Mannheim and other collaboratorsUnknownGIST, Malignant | KIT Gene Mutation | KIT Exon 13 MutationGermany
-
Ariad PharmaceuticalsApproved for marketingChronic Myeloid Leukemia (CML) | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)United States
-
Ariad PharmaceuticalsTerminatedChronic Myeloid LeukemiaUnited States, Australia, Austria, Belgium, Canada, Czech Republic, Finland, France, Germany, Hong Kong, Italy, Korea, Republic of, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, Slovakia, Spain, Sweden, Switz... and more
-
Versailles HospitalActive, not recruiting